Active Thyroid Cancer Specific Trials

For available solid tumor basket trials please e-mail us at scthycc@labiomed.org or call 310-222-8172.

1) Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
2) Phase I Study of BLU-667 (highly selective RET inhibitor) for MTC and PTC
3) Iodine I-131 with or without Selumetinib in Treating Patients with Recurrent or Metastatic Thyroid Cancer
4) A Multicenter, Randomized, Double-blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
5) Phase II Clinical Trial for Tipifarnib for HRAS-mutant Thyroid Cancer
6) Active Surveillance of Papillary Thyroid Microcarcinoma